Intraperitoneal administration of nesfatin-1, a novel anorexigenic peptide, exerted a cardioprotective effect in STZ-induced DCM C57BL/6 J mice model by suppressing the activation of cardiac p38 and subsequently increased glucagon-like peptide-1 (GLP-1) level thereby ameliorating myocardial hypertrophy and heart dysfunction [110]. Here, GCG is linked to cardiac hypertrophy.